Clinical Trial Update: Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing netarsudil 0.02% with ripasudil 0.4% in Japanese patients with primary open angle glaucoma or ocular hypertension; study comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Netarsudil 0.02% ophthalmic solution (netarsudil)
• Ripasudil hydrochloride hydrate 0.4% ophthalmic solution (ripasudil)

Snippet

Sponsor: Aerie Pharmaceuticals | Conditions: Primary Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2023-02-27